Top Page
DocMorris
(DOCM)
DocMorris (DOCM) vs. iShares MSCI Switzerland ETF (EWL)
DocMorris Business Overview & Revenue Model
DocMorris Earnings Call Summary
DocMorris Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.02B | 969.46M | 1.61B | 1.73B | 1.48B |
| Gross Profit | 216.54M | 203.35M | 245.63M | 260.05M | 241.33M |
| EBITDA | -37.02M | -54.57M | -109.79M | -159.35M | -76.13M |
| Net Income | -97.25M | 82.28M | -171.12M | -225.74M | -135.69M |
Balance Sheet | |||||
| Total Assets | 778.13M | 866.42M | 1.10B | 1.27B | 1.28B |
| Cash, Cash Equivalents and Short-Term Investments | 95.37M | 104.03M | 156.40M | 278.20M | 300.97M |
| Total Debt | 312.21M | 330.81M | 528.64M | 525.15M | 526.43M |
| Total Liabilities | 438.02M | 435.89M | 748.67M | 784.29M | 746.74M |
| Stockholders Equity | 340.11M | 430.53M | 350.78M | 484.92M | 531.74M |
Cash Flow | |||||
| Free Cash Flow | -55.21M | -115.12M | -156.58M | -194.11M | -127.34M |
| Operating Cash Flow | -26.60M | -87.42M | -97.29M | -130.63M | -67.51M |
| Investing Cash Flow | 93.88M | 219.82M | -89.77M | -67.33M | -199.86M |
| Financing Cash Flow | -26.00M | -202.63M | 39.11M | 179.72M | 363.25M |
DocMorris Technical Analysis
DocMorris Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | CHF370.36M | ― | ― | 4.91% | 14.99% | ||
57 Neutral | £4.81B | 6.73 | -62.36% | 5.45% | 34.03% | 6.31% | |
| ― | $1.33B | ― | -6.44% | ― | ― | ― | |
| ― | €356.14M | 16.09 | 13.13% | 2.35% | ― | ― | |
77 Outperform | CHF4.37B | 24.33 | 2.61% | 4.67% | -35.91% | ||
71 Outperform | CHF29.65B | 144.42 | 0.12% | 5.91% | ― | ||
71 Outperform | CHF1.06B | 310.05 | ― | 6.05% | 449.69% |
DocMorris Corporate Events
The Federal Court of Justice (BGH) has overturned a previous ruling prohibiting prescription bonuses, aligning with the European Court of Justice’s stance that such bonuses are permissible under EU law. This decision allows DocMorris to reintroduce cash bonuses for prescription medications, reducing patient costs and potentially enhancing its competitive position in the online pharmacy market.
The most recent analyst rating on (CH:DOCM) stock is a Buy with a CHF15.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
DocMorris has received an extension for its CardLink solution approval from gematik until January 2027, facilitating a smooth transition to the new PoPP technology for e-prescription redemption. This extension allows patients to continue using their electronic health cards and the DocMorris App without disruption, ensuring continuity in digital healthcare services and reinforcing DocMorris’s position in the digital health market.
The most recent analyst rating on (CH:DOCM) stock is a Buy with a CHF10.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
DocMorris AG successfully completed its rights offering, with 98.7% of subscription rights exercised, generating approximately CHF 200 million in gross proceeds. This capital increase aims to support the company’s growth in prescription drugs, marketing expenses, and potential bond repayment. The new shares will be listed on the SIX Swiss Exchange, enhancing DocMorris’s financial position and strategic growth plans.
The most recent analyst rating on (CH:DOCM) stock is a Sell with a CHF19.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
Pelion S.A., the largest healthcare company in Poland, has acquired a 9.68% stake in DocMorris AG, marking a significant strategic investment in the Swiss-based online pharmacy and healthcare marketplace. This participation by Pelion, which is active in multiple European countries, is expected to bolster DocMorris’s industry positioning and expand its market influence, particularly given Pelion’s extensive experience in the pharmacy business.
The most recent analyst rating on (CH:DOCM) stock is a Sell with a CHF19.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
DocMorris AG’s shareholders have approved a capital increase through a rights issue to raise approximately CHF 200 million, aimed at financing growth in prescription drugs and achieving positive cash flow by 2027. The capital increase will also support marketing expenses and potentially repay a CHF 95 million convertible bond. The rights issue involves offering new shares to existing shareholders and eligible investors, with trading and settlement scheduled for May 2025.
DocMorris AG announced the final details of its planned capital increase, amounting to approximately CHF 200 million, during its General Meeting. The capital is intended to finance growth in prescription drugs and potentially repay a convertible bond. The company reported a 13.4% increase in external sales in the first quarter of 2025, despite a negative EBITDA, and continues to see growth in its Rx business and telemedicine services. The capital increase is expected to strengthen DocMorris’s market position and support its medium-term financial goals.